Evaluating the effectiveness and utility of a novel culturally

Evaluating the effectiveness and utility of a novel culturally-adapted telemonitoring system in bettering the glycaemic management of Asians with type-2 diabetes mellitus: a blended technique research protocol

Background: Common supervision of sufferers with type-2 diabetes mellitus (T2DM) by healthcare suppliers is crucial to optimise their glycaemic management however is difficult to attain in present care fashions. Telemonitoring is postulated to bridge this hole by leveraging on internet-of-things and mobile-health expertise. This research goals to find out the effectiveness of a novel telemonitoring system (OPTIMUM) in bettering the glycaemic management of sufferers with T2DM in contrast with commonplace of care alone.

Strategies: This mixed-method research contains an preliminary randomised managed trial involving 330 Asian adults with T2DM, aged 26-65 years outdated with an HbA1c of seven.5-10%, with 115 within the intervention and management arms every. These within the intervention arm will use standardised Bluetooth-enabled gadgets to transmit their capillary glucose, blood strain and weight measurements to the OPTIMUM system.

Main care physicians and nurses will remotely supervise them in accordance with an embedded administration algorithm for six months, together with tele-education by way of weekly movies over Eight weeks and asynchronous tele-consultation if irregular or absent parameters are detected. Sufferers in each arms will probably be assessed at baseline, 6, 12 and 24 months post-recruitment.

The first end result will probably be their HbA1c distinction between each arms at baseline and 6 months. Blood strain and weight management; high quality of life, medicine adherence, confidence in self-management, diabetic literacy and associated misery and healthcare utilisation utilizing validated questionnaires; and incident retinal, renal, cardiac and cerebrovascular problems will probably be in contrast between the 2 arms as secondary outcomes at stipulated time-points. Intervention arm sufferers will probably be interviewed utilizing qualitative analysis strategies to grasp their expertise, acceptance and perceived usefulness of the OPTIMUM system.

Dialogue: General, this research seeks to judge the effectiveness of cultural-adapted telemonitoring system in bettering glycaemic management of Asians with type-2 diabetes mellitus in comparison with commonplace of care. The outcomes of this trial will higher inform coverage makers in adopting telemedicine for inhabitants well being administration.

insuline-medical
insuline-medical

RRAD Antibody

1-CSB-PA248209
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody

1-CSB-PA003910
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

RRAD Antibody

1-CSB-PA779820
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

RRAD antibody

70R-50359 100 ul
EUR 292.8
Description: Purified Polyclonal RRAD antibody

RRAD antibody

70R-5797 50 ug
EUR 560.4
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD antibody

70R-5798 50 ug
EUR 560.4
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD Antibody

37229-100ul 100ul
EUR 302.4

Rrad/ Rat Rrad ELISA Kit

ELI-14921r 96 Tests
EUR 1063.2

RRAD Conjugated Antibody

C37229 100ul
EUR 476.4

Polyclonal RRAD Antibody

APR05556G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications:

RRAD siRNA

20-abx932133
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

RRAD Peptide

43-008P 0.1 mg
EUR 405.6
Description: RRAD Peptide

RRAD Blocking Peptide

33R-4793 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797

RRAD Blocking Peptide

33R-10070 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798

RRAD Blocking Peptide

20-abx063234
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

Anti-RRAD (aa36-48) antibody

STJ72757 100 µg
EUR 430.8

Human RRAD shRNA Plasmid

20-abx954199
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

RRAD ELISA KIT|Human

EF005507 96 Tests
EUR 826.8

RRAD Recombinant Protein (Human)

RP095493 100 ug Ask for price

RRAD Recombinant Protein (Rat)

RP226925 100 ug Ask for price

RRAD Recombinant Protein (Mouse)

RP169340 100 ug Ask for price

GTP-Binding Protein RAD (RRAD) Antibody

20-abx008742
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

GTP-binding protein RAD (RRAD) Antibody

abx332370-100ul 100 ul
EUR 510

GTP-Binding Protein RAD (RRAD) Antibody

abx432011-200ul 200 ul
EUR 460.8

GTP-binding protein RAD (RRAD) Antibody

20-abx324872
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

GTP-binding protein RAD (RRAD) Antibody

20-abx241706
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

GTP-binding protein RAD (RRAD) Antibody

20-abx214509
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Rrad ORF Vector (Rat) (pORF)

ORF075643 1.0 ug DNA
EUR 607.2

Rrad ORF Vector (Mouse) (pORF)

ORF056448 1.0 ug DNA
EUR 607.2

RRAD ORF Vector (Human) (pORF)

ORF031832 1.0 ug DNA
EUR 486

Polyclonal RRAD (aa36-48) Antibody (internal region)

APG00807G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications:

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-100ug 100 ug
EUR 469.2

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx237237-100ug 100 ug
EUR 661.2

Rrad sgRNA CRISPR Lentivector set (Rat)

K7052701 3 x 1.0 ug
EUR 406.8

Rrad sgRNA CRISPR Lentivector set (Mouse)

K3480701 3 x 1.0 ug
EUR 406.8

RRAD sgRNA CRISPR Lentivector set (Human)

K2069901 3 x 1.0 ug
EUR 406.8

Rrad sgRNA CRISPR Lentivector (Rat) (Target 1)

K7052702 1.0 ug DNA
EUR 184.8

Rrad sgRNA CRISPR Lentivector (Rat) (Target 2)

K7052703 1.0 ug DNA
EUR 184.8

Rrad sgRNA CRISPR Lentivector (Rat) (Target 3)

K7052704 1.0 ug DNA
EUR 184.8

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3480702 1.0 ug DNA
EUR 184.8

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3480703 1.0 ug DNA
EUR 184.8

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3480704 1.0 ug DNA
EUR 184.8

RRAD sgRNA CRISPR Lentivector (Human) (Target 1)

K2069902 1.0 ug DNA
EUR 184.8

RRAD sgRNA CRISPR Lentivector (Human) (Target 2)

K2069903 1.0 ug DNA
EUR 184.8

RRAD sgRNA CRISPR Lentivector (Human) (Target 3)

K2069904 1.0 ug DNA
EUR 184.8

RRAD Protein Vector (Human) (pPB-C-His)

PV127326 500 ng
EUR 662.4

RRAD Protein Vector (Human) (pPB-N-His)

PV127327 500 ng
EUR 662.4

RRAD Protein Vector (Human) (pPM-C-HA)

PV127328 500 ng
EUR 662.4

RRAD Protein Vector (Human) (pPM-C-His)

PV127329 500 ng
EUR 662.4

RRAD Protein Vector (Rat) (pPB-C-His)

PV302570 500 ng
EUR 723.6

RRAD Protein Vector (Rat) (pPB-N-His)

PV302571 500 ng
EUR 723.6

RRAD Protein Vector (Rat) (pPM-C-HA)

PV302572 500 ng
EUR 723.6

RRAD Protein Vector (Rat) (pPM-C-His)

PV302573 500 ng
EUR 723.6

RRAD Protein Vector (Mouse) (pPB-C-His)

PV225790 500 ng
EUR 723.6

RRAD Protein Vector (Mouse) (pPB-N-His)

PV225791 500 ng
EUR 723.6

RRAD Protein Vector (Mouse) (pPM-C-HA)

PV225792 500 ng
EUR 723.6

RRAD Protein Vector (Mouse) (pPM-C-His)

PV225793 500 ng
EUR 723.6

Rrad 3'UTR Luciferase Stable Cell Line

TU219725 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line

TU168183 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line

TU269725 1.0 ml Ask for price

Rrad 3'UTR Luciferase Stable Cell Line

TU118183 1.0 ml Ask for price

RRAD 3'UTR GFP Stable Cell Line

TU072380 1.0 ml
EUR 1672.8

RRAD 3'UTR Luciferase Stable Cell Line

TU022380 1.0 ml
EUR 1672.8

Human GTP-binding protein RAD (RRAD) ELISA Kit

abx385354-96tests 96 tests
EUR 1093.2

Rat GTP-binding protein RAD (RRAD) ELISA Kit

abx391893-96tests 96 tests
EUR 1093.2

Mouse GTP-binding protein RAD (RRAD) ELISA Kit

abx390415-96tests 96 tests
EUR 1093.2

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV658369 1.0 ug DNA
EUR 616.8

RRAD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV658373 1.0 ug DNA
EUR 616.8

RRAD Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV658374 1.0 ug DNA
EUR 616.8

Human GTP- binding protein RAD, RRAD ELISA KIT

ELI-35549h 96 Tests
EUR 988.8

Mouse GTP- binding protein RAD, Rrad ELISA KIT

ELI-14089m 96 Tests
EUR 1038

Human RRAD And GEM Like GTPase 2 (REM2) ELISA Kit

abx382769-96tests 96 tests
EUR 1093.2

Rrad ELISA Kit| Mouse GTP-binding protein RAD ELISA Kit

EF016057 96 Tests
EUR 826.8

Rrad ELISA Kit| Rat GTP-binding protein RAD ELISA Kit

EF019253 96 Tests
EUR 826.8

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7052705 3 x 1.0 ug
EUR 451.2

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3480705 3 x 1.0 ug
EUR 451.2

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K2069905 3 x 1.0 ug
EUR 451.2

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV658370 1.0 ug DNA
EUR 616.8

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV658371 1.0 ug DNA
EUR 686.4

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV658372 1.0 ug DNA
EUR 686.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7052706 1.0 ug DNA
EUR 200.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7052707 1.0 ug DNA
EUR 200.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7052708 1.0 ug DNA
EUR 200.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3480706 1.0 ug DNA
EUR 200.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3480707 1.0 ug DNA
EUR 200.4

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3480708 1.0 ug DNA
EUR 200.4

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K2069906 1.0 ug DNA
EUR 200.4

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K2069907 1.0 ug DNA
EUR 200.4

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K2069908 1.0 ug DNA
EUR 200.4

ASAP1 antibody Antibody

DF8746 200ul
EUR 420

CD11b Antibody Antibody

ABD2911 100 ug
EUR 525.6

anti- Antibody^Polyclonal antibody control antibody

LSMab09882 100 ug
EUR 525.6

Antibody

A1360-500 Ask for price

Ly1 Antibody Reactive (LYAR) Antibody

20-abx123734
  • EUR 493.20
  • EUR 710.40
  • 100 ul
  • 200 ul

Anti-Glycolipid Antibody (AGA) Antibody

20-abx004855
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Ly1 Antibody Reactive (LYAR) Antibody

20-abx014333
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Ly1 Antibody Reactive (LYAR) Antibody

20-abx008109
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-400ul 400 ul
EUR 627.6

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-80l 80 µl
EUR 343.2

Anti-Glycolipid Antibody (AGA) Antibody

abx036399-100ug 100 ug
EUR 469.2

Anti-Glycolipid Antibody (AGA) Antibody

abx230204-100ug 100 ug
EUR 577.2

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319900
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319901
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319905
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319913
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

20-abx311665
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

20-abx324434
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

abx234901-100ug 100 ug
EUR 661.2

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 332.4
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 332.4

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 332.4

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ25477 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-SEPT8 Antibody antibody

STJ25479 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT2 Antibody antibody

STJ28365 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ28963 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT1 antibody antibody

STJ119580 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012]

Anti-Anti-SEPT12 Antibody antibody

STJ117759 100 µl
EUR 332.4
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-MARCH6 Antibody antibody

STJ118549 100 µl
EUR 332.4

Anti-Anti-MARCH6 Antibody antibody

STJ118550 100 µl
EUR 332.4

Anti-Anti-MARCH7 Antibody antibody

STJ118752 100 µl
EUR 332.4

Anti-Anti-SEPT3 Antibody antibody

STJ118990 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ113941 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ114081 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ114819 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-MARCH8 Antibody antibody

STJ114828 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ116214 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT8 Antibody antibody

STJ117206 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-100ul 100ul
EUR 399.6

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-50ul 50ul
EUR 286.8

Antibody Pair to ApoA-V antibody

10R-1876 100 ul
EUR 781.2
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-01mg 0,1 mg
EUR 321
Description: anti-CD22 monoclonal antibody

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-1000ug 1000 ug
EUR 1539
Description: anti-CD22 monoclonal antibody

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103034
  • EUR 543.60
  • EUR 159.60
  • EUR 1562.40
  • EUR 744.00
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103035
  • EUR 560.40
  • EUR 159.60
  • EUR 1612.80
  • EUR 760.80
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103036
  • EUR 577.20
  • EUR 159.60
  • EUR 1696.80
  • EUR 794.40
  • EUR 427.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Hepatitis C Virus Antibody (HCV) Antibody

abx023924-1mg 1 mg
EUR 1446

Anti-Glycoprotein 210 Antibody (gp210) Antibody

abx233571-100ug 100 ug
EUR 577.2

Anti Deoxyribonucleic Acid Antibody (DNA) Antibody

abx411057-50ug 50 ug
EUR 710.4

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319902
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319903
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319904
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319906
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319907
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319908
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319914
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319915
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319916
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319929
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319930
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319931
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (HRP)

20-abx311666
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (FITC)

20-abx311667
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (Biotin)

20-abx311668
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

Goat anti- human Antibody^Polyclonal antibody

LSMab09896 100 ug
EUR 525.6

Antibody for Human alpha Tubulin Antibody

SPC-692D 0.1mg
EUR 424.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A390 0.1mg
EUR 481.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A488 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A594 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700.

Antibody for Human alpha Tubulin Antibody

SPC-692D-ALP 0.1mg
EUR 472.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase.

Antibody for Human alpha Tubulin Antibody

SPC-692D-APC 0.1mg
EUR 478.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC .

Antibody for Human alpha Tubulin Antibody

SPC-692D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7.

Antibody for Human alpha Tubulin Antibody

SPC-692D-BI 0.1mg
EUR 475.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350.

[Prevalence and incidence of type 2 diabetes in Iceland 2005-2018]

Introduction: The variety of folks with kind 2 diabetes has elevated in Iceland in the previous couple of a long time. We utilized the nationwide database on prescribed medicine from the Directorate of Well being to estimate the prevalence and incidence of kind 2 diabetes in Iceland and made prediction on the prevalence of kind 2 diabetes in Iceland in 10 and 20 years.

Materials and strategies: Prevalence and incidence of kind 2 diabetes for the interval 2005-2018 was estimated primarily based on prescriptions of diabetes medicine within the nationwide prescription database containing all prescriptions in Iceland through the interval. The consequence was in comparison with the consequence from the REFINE-Reykjavik research (potential, population-based cohort research) from 2004 to 2011 and printed knowledge from the USA from 1980 to 2016.

Outcomes: The prevalence of kind 2 diabetes greater than doubled in close to all age teams in each women and men within the interval 2005-2018. The incidence elevated by 2.8% yearly (in 18-79 years outdated). The variety of folks in Iceland with kind 2 diabetes was 10600 in 2018 and had increased from 4200 within the 12 months 2005. Comparability with the outcomes of the REFINE-Reykjavik research confirmed an underestimation (29% in women and men) of the prevalence of kind 2 diabetes. If the rise in kind 2 diabetes continues at an analogous fee as within the years 2005-2018 the variety of folks with diabetes in Iceland might be close to 24000 within the 12 months 2040.

Conclusion: Linear improve was seen in incidence and prevalence of individuals with kind 2 diabetes within the years 2005-2018. Related evolution was seen in USA from 1984. To be able to counteract the rise of kind 2 diabetes following the identical path as has been seen within the USA, focused measures are wanted.

The Impact of Monetary Incentives on High quality Measures within the Remedy of Diabetes Mellitus: a Randomized Managed Trial

Background: Monetary incentives are sometimes used to enhance high quality of care in continual care sufferers. Nonetheless, the proof in regards to the impact of monetary incentives continues to be inconclusive.

Goal: To check the impact of monetary incentives on high quality measures (QMs) within the remedy of sufferers with diabetes mellitus in main care. We incentivized a scientific QM and a course of QM to check the impact of monetary incentives on various kinds of QMs and to research the spill-over impact on non-incentivized QMs.

Design/members: Parallel cluster randomized managed trial primarily based on digital medical data database involving Swiss normal practitioners (GPs). Practices had been randomly allotted.

Intervention: All members acquired a bimonthly suggestions report. The intervention group moreover acquired potential monetary incentives on GP degree relying on their efficiency.

Fundamental measures: Between-group variations in proportions of sufferers fulfilling incentivized QM (course of QM of annual HbA1c measurement and scientific QM of blood strain degree beneath 140/95 mmHg) after 12 months.

Key outcomes: Seventy-one GPs (median age 52 years, 72% male) from 43 completely different practices and subsequently 3838 sufferers with diabetes mellitus (median age 70 years, 57% male) had been included. Proportions of sufferers with annual HbA1c measurements remained unchanged (intervention group decreased from 79.Zero to 78.3%, management group from 81.5 to 81.0%, OR 1.09, 95% CI 0.90-1.32, p = 0.39). Proportions of sufferers with blood strain beneath 140/95 improved from 49.9 to 52.5% within the intervention group and decreased from 51.2 to 49.0% within the management group (OR 1.16, 95% CI 0.99-1.36, p = 0.06). Proportions of non-incentivized course of QMs elevated considerably within the intervention group.

Conclusion: GP degree monetary incentives didn’t end in extra frequent HbA1c measurements or in improved blood strain management. Curiously, we might verify a spill-over impact on non-incentivized course of QMs. But, the mechanism of spill-over results of monetary incentives is essentially unclear.

 

Glycemic outcomes associated to melancholy in adults with kind 1 diabetes

Glycemic outcomes of adults with kind 1 diabetes could also be affected by melancholy. Our goal was to match outcomes of “depressed” (Affected person Well being Questionnaire-9 ⩾ 10, N = 83) to “not-depressed” matched management (Affected person Well being Questionnaire-2 < 3, N = 166) adults with kind 1 diabetes with goal measures.

The depressed group had poorer blood glucose management and, for these with glucose meter downloads, fewer glucose assessments/day. The teams didn’t differ on glucose variability or episodes of hypoglycemia. Despair in adults with kind 1 diabetes is related to poorer glycemic management and fewer blood glucose monitoring. Future analysis ought to study whether or not remedy of melancholy ends in higher self-care and glycemic outcomes.

 

, , , , , ,

Post navigation

Leave a Reply

Your email address will not be published. Required fields are marked *